Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063751 · ClinicalTrials.gov registry record · NA
Tritanium® Primary Acetabular Shell Study
A NA study, sponsored by Stryker Orthopaedics.
- Terminated
- Registry status
- NA
- Development phase
- 275
- Enrollment target
NCT01063751 is a NA study that was terminated before completion, run by Stryker Orthopaedics. The registered enrollment target is 275 participants.
The verdict
NCT01063751, a NA study, was terminated before completion, sponsored by Stryker Orthopaedics.
- TERMINATED
- Registry status
- NA
- Development phase
- 275 participants
- Enrollment target
Study Summary
This study will be a prospective, non-randomized evaluation of the Tritanium® Acetabular Shell for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. Half of the cases will use the Trident® X3® polyethylene insert alone as the bearing surface; the other half will use the modular dual mobility (MDM™) liner coupled with a compatible anatomic dual mobility (ADM™)/MDM™ X3® insert as the bearing surface. The success rate, defined as freedom from acetabular revision for any reason, for hips implanted with the Tritanium® Acetabular Shell, is no worse than for hips implanted with similar technology as reported in the literature and Trident® X3® Study historical control at 5 years postoperative.
Interventions
- DEVICE Tritanium® Primary Acetabular Shell
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2011-07 |
| Est. Completion | 2023-12-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063751
The ClinicalTrials.gov registry entry for NCT01063751 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stryker Orthopaedics, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tritanium® Primary Acetabular Shell is the first listed.
NCT01063751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01063751 about?
NCT01063751 is a clinical study titled "Tritanium® Primary Acetabular Shell Study". This study will be a prospective, non-randomized evaluation of the Tritanium® Acetabular Shell for primary total hip replacement (THR) with a cementless application in a consecutive series of patients who meet the eligibility criteria. Half of the cases will use the Trident® X3® polyethylene insert ...
What is the current status of trial NCT01063751?
This trial is currently terminated. It is a NA study. The enrollment target is 275 participants. The study started on 2011-07. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT01063751?
The interventions under investigation include: Tritanium® Primary Acetabular Shell (DEVICE).
Who is sponsoring clinical trial NCT01063751?
This trial is sponsored by Stryker Orthopaedics, which has 27 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.